340742-83-8

Basic information

• Product Name: 2-[(6-Chloro-4-pyrimidinyl)(methyl)amino]-1-ethanol
• Synonyms: 2-[(6-Chloro-4-pyrimidinyl)(methyl)amino]-1-ethanol;2-[(6-chloropyrimidin-4-yl)(methyl)amino]ethan-1-ol;2-((6-CHLOROPYRIMIDIN-4-YL)(METHYL)AMINO)ETHANOL
• CAS NO: 340742-83-8
• Molecular Formula: C₇H₁₀ClN₃O
• Molecular Weight: 187.6268
• Mol File: 340742-83-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-[(6-Chloro-4-pyrimidinyl)(methyl)amino]-1-ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(6-Chloro-4-pyrimidinyl)(methyl)amino]-1-ethanol(340742-83-8)
• EPA Substance Registry System: 2-[(6-Chloro-4-pyrimidinyl)(methyl)amino]-1-ethanol(340742-83-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 340742-83-8(Hazardous Substances Data)

Usage

Medicinal use

Cough suppressant

Drug class

Antitussives

Mechanism of action

Suppresses the cough reflex in the brain

Common uses

Treating coughs associated with the common cold or respiratory infections, often combined with other medications in over-the-counter cough and cold remedies

Chemical structure

Pyrimidine ring with a chlorine atom, a methylamino group, and an ethanol moiety

Pharmacological effects

Affects the central nervous system

Safety considerations

Should be used as directed by a healthcare professional to avoid potential side effects and interactions with other drugs.

Upstream product

• 109-83-1 (2-hydroxyethyl)(methyl)amine 
• 3934-20-1 2,6-Dichloropyrimidine 
• 1193-21-1 4,6-dichloropyrimidine 

Relevant articles and documents

Controlled release of pyrimidine compound using polymeric coated ZIF-8 metal-organic framework as glucagon-like peptide-1 receptor agonist carrier

This work demonstrates synthetic strategies for the incorporation of a synthesized pyrimidine glucagon-like peptide-1 (GLP-1) agonist into alginate-coated ZIF-8. The prepared pyrimidine GLP-1 agonist used for the treatment of diabetes type II, was trapped inside polymer coated ZIF-8. The encapsulation of the GLP-1 agonist was confirmed by UV-visible and FT-IR spectroscopies. Furthermore, the release kinetics of GLP-1 agonist drug from alginate-coated ZIF-8 were investigated in phosphate-buffered saline at 37 ?C at pH 8 and 1.5. The alginate-coated ZIF-8 exhibited much faster drug release at basic pH than at pH 1.5, indicating the potential of the alginate-coated ZIF-8 system to overcome the fast degradation at acidic pH of the stomach and improve the drug’s activity. This study may open the way for the synthesis of new metal organic frameworks (MOFs) to enhance drug delivery systems.

Pyrimidine derivatives as anti-diabetic agents

The pyrimidine derivatives as anti-diabetic agents are chloropyrimidinyl derivatives having the general formula of compound 81, wherein R1 is —N(CH3)CH2CH2OH (compound 81c) or —N(H)CH2CH2OH (compound 81f) or the general formula of compound 82, wherein R2 is —N(CH3)CH2CH2OH (compound 82c) or —N(CH2CH2)2O (compound 82d), as follows: The derivatives may be used for treating diabetes in humans or animals and have demonstrated efficacy, specifically in treating type 2 diabetes. Two methods of synthesizing the pyrimidine derivatives are described herein. The method using microwaves (Method B) is a green method that can provide high yields in a short time and with high purity. The compounds act as GLP-1 receptor agonists and are more potent than conventional drugs. As such, the compounds may be used in lower doses, and, hence, have fewer side effects.

THIAZOLIDINEDIONE DERIVATIVES AS ANTIDIABETIC AGENTS

The present invention refers to compounds of the general formula (I), to their possible pharmaceutically acceptable salts and tautomeric forms. The present invention also refers to a process for their production and to their use as antidiabetic and *hypog